hsa-miR-224-5p

ncRNA information

ncRNA name

hsa-miR-224-5p

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Prognosis

Upstream regulatory factors

Not available

Downstream target

PRKCD

Cancer information

Cancer name

Ovarian Papillary Serous Carcinoma

Cancer site

Ovary

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Upregulation of miR-224-5p increases cell survival of chemosensitive cell lines to cisplatin.

Tissue resource

ovarian papillary serous carcinoma samples

ovarian cancer cisplatin-resistant cell lines C13

ovarian cancer cisplatin-resistant cell lines A2780CP

ovarian cancer cisplatin-sensitive cell lines OV2008

ovarian cancer cisplatin-sensitive cell lines A2780S

Experiment

qRT-PCR,Western blot


Institute

Second Affiliated Hospital of Dalian Medical University

Country

China

Continent

Asia